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Abstract 
 
Objective: People with non-dialysis dependent chronic kidney disease (CKD) and renal transplant 
recipients (RTR) have compromised physical function and reduced physical activity (PA) levels. 
Whilst established in healthy older adults and other chronic diseases, this association remains 
underexplored in CKD. We aimed to review the existing research investigating poor physical 
function and PA with clinical outcome in non-dialysis CKD.  
Data sources: Electronic databases (PubMed, MEDLINE, EMBASE, Web of Science, Cochrane 
Central Register of Controlled Trials) were searched until December 2017 for cohort studies 
reporting objective/subjective measures of PA/physical function and the associations with adverse 
clinical outcomes/all-cause mortality for patients with non-dialysis chronic kidney disease stages 1 
to 5 and RTR. The protocol was registered on the International Prospective Register of Systematic 
Reviews (PROSPERO) (CRD42016039060). 
Review methods: Study quality was assessed using the Newcastle-Ottawa Scale and the Agency 
for Healthcare and Research Quality (AHRQ) standards. 
Results: 29 studies were included; 12 reporting on physical function and 17 on PA. Only 8 studies 
were conducted with RTR. The majority were classified as “Good” according to the AHRQ 
standards. Although not appropriate for meta-analysis due to variance in the outcome measures 
reported, a coherent pattern was seen with higher mortality rates and/or prevalence of adverse 
clinical events associated with lower PA and physical function levels, irrespective of the 
measurement tool used. Sources of bias included incomplete description of participant flow through 
the study and over-reliance on self-report measures.  
Conclusions: In non-dialysis CKD, survival rates correlate with greater PA and physical function 
levels. Further trials are required to investigate causality and the effectiveness of physical 
function/physical activity interventions in improving outcomes. Future work should identify 
standard assessment protocols for PA and physical function. 
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Introduction 
 
Chronic kidney disease (CKD) is a long term condition affecting approximately three million 
people in the UK and >61,000 people have end stage renal disease and require dialysis or a renal 
transplant(1). Research into kidney disease has historically tended to concentrate on patients with 
severe renal impairment requiring renal replacement therapy, however there is a significant 
proportion of the UK population living with earlier stage CKD and interventions to promote a 
healthy lifestyle with this group are starting to emerge.  
 
People living with non-dialysis CKD experience a high symptom burden with progressively 
impaired physical function and low levels of physical activity (PA). These negatively affect quality 
of life (QoL) and independence(2, 3). In non-dialysis CKD patients, even a small increase in regular 
PA levels can improve self-reported quality of health and life, as well as improving exercise 
tolerance and cardiovascular reactivity(4). In older adults(5), and in other chronic disease 
populations such as diabetes(6, 7), it is well-established that both reduced physical function and PA 
are associated with an increased risk of cardiovascular disease (CVD) and all-cause mortality(8, 9). 
Whilst evidence is limited in non-dialysis chronic kidney disease populations, it is well established 
in patients undergoing dialysis that both self-reported(10-13) and objective(13-15) physical function 
is a significant and independent predictor of all-cause mortality and future hospitalisation. Notably, 
regularly physically-active dialysis patients have a decreased risk of CVD and death(16), however 
the physiological and social impact of dialysis is such that findings in this group are not directly 
transferable to a patient population that does not require renal replacement therapy. Although renal 
transplant recipients (RTR) generally report improved physical function, PA, and QoL following 
transplantation, it often remains poor(17, 18), and patients who have undergone transplantation 
remain at high risk of CVD(19). 
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Physical function and PA are two key ‘modifiable’ lifestyle factors that may reduce mortality and 
clinical adverse events and have a positive impact on quality of life in non-dialysis CKD and RTR. 
Furthermore, early identification, using simple physical function or physical activity measures, of 
patients at risk of clinical adverse events may focus interventions (e.g., exercise or nutrition) 
designed to improve such outcomes.  
 
Physical function and PA should be viewed as two independent concepts. Physical function is the 
ability to perform activities of daily living, and is assessed using simple tests to reflect these tasks 
(e.g. getting out of a chair) or by subjectively rating competency in completing different tasks(13). 
PA is any bodily movement produced by contraction of skeletal muscle that increases energy 
expenditure above a basal level(20). PA and physical function correlate significantly and both 
concepts are important to clinicians and patients, hence this review will explore the relationship of 
each with clinical outcomes.  
 
We performed a systematic review to identify the association between physical function and PA 
with all-cause mortality and other adverse clinical outcomes in non-dialysis CKD (i.e. including 
RTR). No systematic review of the current literature has been performed on this association in this 
patient group. We hypothesised that patients with non-dialysis CKD who are functionally limited or 
less physically active will demonstrate a higher risk of all-cause mortality and adverse clinical 
outcomes.  
6 
 
Methods 
 
Protocol and registration 
The protocol was registered on the International Prospective Register of Systematic Reviews 
(PROSPERO) (CRD42016039060). Data is reported in line with the ‘Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses’ (PRISMA) guidelines(21). 
 
Search strategy and selection criteria 
We aimed to identify observational studies that explored the link between physical function, PA, 
and adverse clinical outcomes and all-cause mortality in non-dialysis CKD. The primary question of 
interest was the association between objective and subjective measures of physical function, PA, 
and the likelihood of death (i.e. all-cause mortality) and adverse clinical outcomes in patients with 
CKD not currently requiring dialysis therapy. For the purpose of this review, an ‘adverse clinical 
outcome’ was defined as one (or more) of the following events: end-stage renal disease (i.e. the 
need for/time to dialysis), unforeseen hospital admission, or non-fatal cardiovascular event (e.g., 
myocardial infarction, stroke, etc.). The primary outcome of interest was all-cause mortality.  
 
Data sources and search strategy 
The following electronic databases were searched from their date of establishment to July 2016 and 
a further search was performed in December 2017 to gather any new literature. National Centre for 
Biotechnology Information (NCBI) PubMed (which includes the Medical Literature Analysis and 
Retrieval System Online (MEDLINE)), Excerpta Medica dataBASE (EMBASE), Web of Science 
(WOS) (which includes the KCI-Korean Journal Database, MEDLINE, Russian Science Citation 
Index, and SciELO Citation Index), and the Cochrane Central Register of Controlled Trials 
(CENTRAL). The search strategy was tailored to each database and used a combination of key 
words and medical subject headings (MeSH). MeSH search terms were: “kidney diseases”, “kidney 
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transplantation”, “physical activity”, “mortality”, “death”, “cardiovascular event”. Other non-MeSH 
search terms used were: “renal impairment”, “physical function”, “physical performance”, 
“disability”, “all-cause mortality”, “cardiovascular diseases”; “adverse event”, “hospital 
admission”. 
 
As per the PRISMA statement, an example full electronic search strategy can be found for the 
NCBI PubMed database in supplementary material 1. 
 
Article eligibility criteria 
The eligibility for full text review of each citation was independently evaluated by two authors 
(HJM, TJW) on the basis of title and abstract. Any article deemed potentially relevant was retrieved 
for full-text review. The reference lists of any relevant articles were also screened to identify studies 
which may have been missed in the search.  
 
Inclusion criteria: 
1. Human adults (aged 18 years or over); 
2. CKD (any stage) or RTR; 
3. Cohort studies including secondary analysis of randomised control trials and abstracts; 
4. Reporting physical function or PA outcome measures; 
5. Reporting association with adverse clinical outcomes and all-cause mortality in either unadjusted 
or adjusted terms. 
 
Specific exclusion criteria: 
1. Renal failure - any dialysis modality; 
2. Review articles; 
3. Animal trials; 
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4. Non-English articles. 
 
Data extraction 
Following a preliminary pilot search in NCBI PubMed, a data extraction form was created to 
capture relevant information from included studies. Each article was reviewed by two independent 
members of the research team during the data extraction process. The following information was 
extracted for each study:  
 
1. Study characteristics: such as the year of publication, study design, and sample size;  
2. Patient characteristics, such as mean age, sex distribution, race, and comorbidities;  
3. Definitions and incidences of: CKD, physical function (or its associated domains), PA, clinical 
adverse events, and all-cause mortality; 
4. Reported association of physical function or PA with adverse clinical outcomes and/or all-cause 
mortality in either unadjusted or adjusted terms (e.g., hazard or odds ratio). 
 
Evaluation of quality and risk of bias 
Each study was evaluated for quality and risk of bias using the Newcastle-Ottawa Scale (NOS)(22) 
independently by two reviewers. Discrepancies in scoring were settled by mutual agreement. 
Primary authors HJM and TJW had the final verdict decision. The NOS is a quality evaluation 
method for non-randomized studies which uses three criteria: Selection, Comparability, and 
Outcome. Each study is designated a number of stars for each section, based on predetermined 
queries(22). The NOS has been extensively used to evaluate quality and bias for systematic reviews 
and meta-analyses and is recommended by the Cochrane Collaboration(23). Scores from the NOS 
were transformed into Agency for Healthcare Research and Quality (AHRQ) standards (‘Good’, 
‘Fair’, and ‘Poor’ quality)(22).  
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Results 
 
Study selection 
A total of 6299 records were identified by systematic searching and 249 were deemed appropriate 
based upon the title and abstract alone. Upon removal of 211 duplicates, 38 records were assessed 
against the full eligibility criteria and 14 records were removed. One additional source was 
identified during the original review process. In December 2017, a re-search found 4 additional 
studies. A total of 29 trials were reviewed (see PRISMA diagram, Figure 1). 
 
Study characteristics 
Overall, the articles demonstrated a range of follow-up times (median follow-up = 7.0 years; range 
1(24)- 15.9 years(25)) and sample sizes (median = 719; range 26(26)- 50,620(27)). Studies were 
conducted in the USA(25, 28-41),Taiwan(27, 42-44), Estonia(26), the Netherlands(45), Korea(46), 
the UK(47, 48), Italy(24), Hungary(49), Brazil(50), Finland(51), and Slovakia(52) ensuring data 
from a variety of cultures are included which, although increasing generalisability, may mean 
culturally specific behaviour trends are masked. Studies included single- (25, 26, 38, 42-45, 47, 49, 
50, 52) and multi-centre investigations(24, 30, 33-37, 39-41, 48, 51), and population-wide 
surveys(27-29, 31, 32, 46). The majority of these studies are observational except Pechter et al(26) 
who described a 10 year programme of supervised hydrotherapy exercise, and Chen et al(30) who 
reported observational data collected as part of an RCT investigating effects of different diets in 
kidney disease. 
 
The disease populations studied varied with 19 investigations conducted in non-dialysis CKD(24, 
26-29, 31-33, 35, 37, 39, 40, 42, 43, 46, 47, 50, 53, 54), seven with RTR(36, 38, 41, 45, 48, 49, 52), 
and Tikkanen-Dolenc et al(51) studied both CKD and RTR. Some studied all five stages of 
CKD(24, 26-28, 34, 39, 43, 44, 46, 47, 51), whilst others studied a fixed eGFR range(29-34, 37, 40, 
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42, 50). Gulati et al(25) studied a female only population with no pre-existing diagnosis of CKD, 
however the mean eGFR of the study population was 53.7 ml/min/1.73m² and 79% were found to 
have an eGFR <60ml/min/1.73m². Further, Robinson-Cohen et al(34) conducted a general 
population study but calculated HR for stratified eGFR bands and, henceforth, both of these papers  
have been included in the review. Two papers(39, 50) investigated physical function as a subset of 
another concept: Delgado et al(39) investigated frailty in CKD, whilst Periera et al(50) studied the 
incidence of sarcopenia. Similarly Chang et al(43) measured hand-grip strength (HGS) to 
investigate the effects of protein-energy wasting.  
 
The association between physical function and all-cause mortality or adverse clinical outcomes are 
summarised in Table 1, and studies reporting the association between PA and outcomes can be 
found in Table 2. Ten papers investigated physical function, whilst 15 studied PA. Two papers used 
cumulative measures using both PA and physical function(34, 38), however these have been 
included in the table corresponding to the main emphasis of the individual trial. Tsai et al(44) 
investigated physical function as “indices” of the person’s ability to engage in PA in addition to 
reporting PA behaviour. 
 
Outcomes reported 
The majority of the papers studied mortality, either as all-cause(24-33, 36, 38-43, 45-52) or cardio-
vascular mortality(37, 45). Other outcomes reported included prevalence of frailty(39), 
sarcopenia(50), protein-energy wastage(43), major adverse cardio-vascular event(44), first 
hospitalisation(44), rate of decline of renal function(34, 35), or risk of requiring dialysis(26, 42-44). 
One study reported an odds ratio of developing diabetic nephropathy(27).  
 
Overall, the results showed that poorer physical function and lower PA was associated with 
increased mortality rates, however differing methodologies preclude meta-analysis. Hazard ratios 
11 
 
were reported in some studies (summarised in Table 1) varying from 1.04(52) to 5.7(24) dependent 
on measurement type and population studied. 
 
Only four papers(36, 38, 45, 51) reviewed the importance of being active with a renal transplant and 
four(41, 48, 49, 52) of the 10 papers investigating physical function studied renal transplant 
recipients. Outcomes studied were all-cause mortality(36, 38, 41, 45, 48, 49, 51, 52), cardio-
vascular mortality(45), graft failure(38, 45, 48, 49), and death with a functioning transplant(36, 49). 
Higher PA levels both prior to transplantation(36) and post-transplant(38, 45) were associated with 
lower mortality rates. Similarly lower physical function levels were associated with increased 
mortality hazard ratios(48, 49, 52). 
 
Objective physical function  
Six papers used objective measures of physical function including the Short Physical Performance 
Battery (SPPB)(24, 41), HGS(43, 44, 50), using a Bruce protocol treadmill test to determine 
cardiorespiratory fitness(25), the ‘timed-up-and-go’ (TUAG)(40), the 6 minute walk test 
(6MWT)(40), 30 second chair stands(44), 2 minute step(44) and gait speed(40). The Short Physical 
Performance Battery (SPPB), TUAG, the 6MWT, and gait speed were independently associated 
with increased all-cause mortality(24, 40, 41). Greater scores in the 2 minute step were correlated 
with a reduced risk of commencing dialysis(44). The number of chair stands achieved in 30 seconds 
was shown to correlate with reduced risk of a major adverse cardio-vascular event and with all-
cause hospitalisation(44). Since both TUAG and the SPPB include measured of a person’s gait 
speed and ability to stand from a chair, it may be inferred that a measure of physical function 
utilising walking and standing provides a useful measure of physical function in CKD when 
outcomes are to be studied.  
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HGS was measured in three studies(40, 43, 50), with inconsistent results. Pereira et al(50) measured 
HGS as a marker of saropaenia which was demonstrated to correlate with mortality risk; 
Roshanravan et al(40) found HGS was relatively preserved compared to lower limb strength, as 
6MWT, gait speed, and TUAG had greater area under the ROC values than HGS. However, Chang 
et al(43) found that HGS was an independent outcome predictor in CKD. 
Cardiorespiratory fitness was found to modify the association between eGFR and mortality(25). A 
maximum cardiorespiratory fitness level of <5 METS (Metabolic Equivalent of Task ~17.5 
ml/kg/min) combined with an estimated glomerular filtration rate (eGFR) of <45 mL/min/1.73 m² 
was associated with increased mortality rates compared to those with better fitness and higher 
eGFR(25).  
 
Objective physical activity  
Only one study(29) used an objective PA measure (i.e. accelerometry), whilst another(34) 
combined gait speed with a questionnaire to give a cumulative PA score. 
 
Subjective physical function  
Self-report measures of physical function were used by six papers(39, 46-49, 52). The 36-item 
Short Form survey ‘SF-36’ was used in three of these(48, 49, 52) and a significant relationship 
between the ‘Physical Component Score’ (PCS) and outcomes was consistently demonstrated. The 
other subjective methods used included ‘Modification of Diet in Renal Disease (MDRD) Quality of 
Wellbeing measure’(39), ‘Korean version of ADL’s’(46), ‘Instrumental ADL’(46), ‘Health Related 
Quality of Life (HRQoL)’(48) and ‘Kidney Disease Quality of Life measure (KDQoL)’(49) which 
included ‘HRQoL’, ‘SF-36’ and ‘Center for Epidemiologic Studies Depression Scale’ (CES-D). 
Similar trends were seen between poorer outcomes and lower physical function. 
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Subjective physical activity  
Thirteen studies which explored PA associations used questionnaires including ‘Household Adult’ 
questionnaire(28, 32) (a translated version was used by Tsai et al(44)), ‘Leisure Time Physical 
Activity Questionnaire’(31), ‘Modified Diet in Renal Disease Leisure Time Physical Activity 
Questionnaire’ (MDRD-LTPAQ)(30), ‘Four-Week Physical Activity History Questionnaire 
(FWH)’(35), ‘Multi-Ethnic Study of Atherosclerosis (MESA) Typical Week Physical Activity 
Survey’(33), ‘Physical Activity Scales for the Elderly’ (PASE)(36), ‘Minnesota Leisure Time PA’ 
questionnaire(37, 45) (a translated version was used by Tikkanen-Dolenc et al(51)), and ‘Tecumseh 
Occupational Activity Questionnaire’(45). One study(27) failed to report which method was used 
and two used clinician judgement to classify PA(38, 42). Questionnaires were frequently used in 
conjunction with a compendium of activities to give MET score for further analysis(27, 28, 31-33, 
36, 44, 45, 51). 
 
The most common PA reported was walking, with data showing that increasing walking duration 
and intensity correlates with favorable health benefits. The dose-response relationship remains 
unclear. Navaneethan et al(31) and Ricardo et al(33) demonstrated reduced mortality risk only when 
guideline PA levels were achieved (i.e. >150mins/week moderately-vigorous PA) whilst Beddhu et 
al(29) found replacing sedentary time with light activity resulted in a lower mortality risk but 
upgrading to moderate/vigorous PA did not reduce the risk further. Robinson-Cohen et al(35) found 
the risk of developing end stage renal disease decreased with every 60 min/week increase in PA 
with the largest reduction when >150minutes was achieved. Similarly, Tikkanen-Dolenc et al(51) 
stratified HR’s according to intensity, duration and frequency of PA and demonstrated increased 
HR’s when each of these differed from the guideline amounts, with the greatest increase in risk 
when target duration of PA was not achieved. In contrast, Tsai et al(44) found no change in hazard 
ratios with PA levels as measured by questionnaires, but found that various functional measures 
were significant. Whilst these studies demonstrate interesting, although conflicting, conclusions, 
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despite large sample sizes, the P values reported are often not significant(35) or not specified(29, 
31, 33). 
 
 
Risk of bias  
Each study was evaluated for quality and risk of bias using the Newcastle-Ottawa Scale and Agency 
for Healthcare Research and Quality (AHRQ standards. These results are summarised in Table 3. 
Overall the quality of these papers was mixed, with 20 classed as ‘Good’, 7 as ‘Fair’ and 2 
determined to be ‘Poor’ quality. Sources of potential bias identified included not fully describing 
the participant flow through the study and the use of self-report measures.  
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Discussion 
 
Summary of review findings  
Overall, our review has shown that, in patients with non-dialysis CKD, reduced physical function 
and PA levels are associated with increased mortality and adverse clinical events, including decline 
in renal function, increased risk of requiring renal replacement therapy, and poor renal graft survival 
(RTR only). Similar observations have been observed in dialysis patients(16) and in other chronic 
populations(6, 7). This has important clinical implications, potentially providing an opportunity to 
improve outcomes. The concepts of PA and physical function have significant overlap and although 
engagement in functional tasks can be considered a category of PA, function can also be considered 
an antecedent of activity. The two concepts are also frequently intertwined in the literature which 
necessitated the consideration of the two ideas in the same review. 
 
Bias was assessed in this review using the NOS. Interestingly, the papers studying disease 
progression were scored negatively by the NOS as the outcome, i.e. CKD, was present at the start of 
the trial and this represents a weakness for this scoring system. Hazard ratios were reported in 
many, but not all, papers, however, some studies reported mortality risk whilst others reported 
survival analysis, making the data unsuitable for meta-analysis. Studies which yielded hazard ratios 
were calculated both as unadjusted models and adjusted for confounding variables, such as age, 
body mass index (BMI), gender, depression, and kidney function levels; however sensitivity 
analysis to confirm these findings was poorly reported.  
 
It is important to state the difficulty deducing causality from the data presented, as patients with 
greater illness burden are often less active and have a reduced functional level. Further longitudinal 
studies are needed whereby interventions increase PA or physical function to assess resultant 
changes in outcomes. Further research is needed into the potential dose-response of PA, and whilst 
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it appears that being active on most days, in line with the current PA recommendations, is 
beneficial, even low levels of PA may confer some benefit in renal patients. It is also important to 
consider that there is a physical function minima, below which PA is impossible. Whilst in 
principle, encouraging patients to be more active may be a straightforward suggestion, the 
complexity of successful behaviour change interventions should not be underestimated. 
 
The data was not appropriate for meta-analysis due to the variance in the measurement outcomes 
and the analysis methods used. This demonstrates the need to identify accepted norm assessments 
of physical function and PA to use in the renal community to allow comparison between 
interventions. The paucity of research in the transplant population is also demonstrated in regard to 
both PA and physical function. 
 
Physical function and outcome 
Reduced physical function was found to correlate with frailty, sarcopenia, and protein-energy 
wastage which, in turn, are associated with mortality. Despite the potential confounders introduced 
by investigating these wider concepts, the value of maintaining functional ability and activity levels 
remained clear. Only one paper(49) assessed depression as a co-variant when exploring the 
relationship between physical function and mortality. Once the hazard ratio analysis was adjusted, 
the significance of the model dropped. Due to the frequent concomitance of depression and 
functional loss, further investigations are required to determine whether this is a trend as yet 
uncharted, or a coincident pattern.  
 
Doyle et al.(47) assessed physical function using the Barthel score, where ability to engage in 
activities of daily living is assigned an ordinal score, and demonstrated a higher score on hospital 
discharge was associated with a lower risk of all-cause mortality. Whilst this score is frequently 
used by clinicians as an objective measure, it is unclear in this paper whether it was used objectively 
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or as a self-report tool. Ricardo et al(32) calculated a ‘healthy lifestyle score’, based on BMI, PA 
levels, dietary intake, and smoking behaviour. Their results demonstrated a positive relationship 
between a ‘healthy’ lifestyle and mortality rates but it is difficult to isolate the effect of PA.  
 
Objective tests were more commonly used to measure physical function. A gait speed reduction of 
0.1m/s was associated with a 26% increased mortality risk, whilst a 1-second longer TUAG score 
correlated with an 8% increased risk of death(40). Thus these objective tests could be useful 
prognostic tools in chronic kidney disease, and may provide interventional targets yielding direct 
patient benefit. HGS measurements generated inconsistent results and hence requires further 
investigation before recommendations can be made about its use as an outcome measure in non-
dialysis CKD.  
 
Physical activity and outcome 
Interestingly, Pechter et al(26) found a 100% survival in patients who maintained engagement in a 
10 year hydrotherapy programme, compared to 55% in the control group (no exercise) who either 
died or required renal replacement therapy. However it may be argued that only the patient group 
with a low co-morbidity burden are able to engage continuously in this type of intervention which 
may confound these results. It must be considered that financing such supervised exercise for the 
entire CKD population is untenable under modern health systems. Conversely, Chen et al(30) 
reported no change in mortality risk with higher PA levels, although the authors acknowledge the 
data’s wide confidence intervals. Also, the sample studied was generally more active than a general 
CKD cohort with 50% walking or exercising regularly. 
 
Measurement of PA should be conducted using objective accelerometry where possible, however 
only one paper utilised this outcome measure. This diversity of PA measures also means that cut-
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offs determining ‘activity’ or ‘inactivity’ vary widely, and as such, different constructs are being 
compared. This also limits exploration of dose-response effects and potential benefits.  
 
Outcome measure use 
A key finding from this review was the large breadth of measures used to assess both physical 
function and PA. Both objective and subjective measures were used, and whilst each confer their 
own strength and limitations, the heterogeneity makes it difficult to compare effects and prevents 
meta-analysis. In many instances, questionnaire-based assessments were used, particularly in the 
measurement of PA level. This has substantial limitations in regard to recall bias and desirable 
responses and for some of these questionnaires validity in the renal population remains 
undemonstrated. Some questionnaires were administered by interviewers(30-32, 37, 45) which may 
have increased completion rates and corrected one of the common criticisms of questionnaire use. 
In Yango et al(38), retrospective clinician judgement on patient PA level was used, and such 
subjectivity means minimal conclusions can be drawn from this trial. Methodological flaws were 
also demonstrated by Chen et al(42) who asked participants and their care-givers to recall a 3 month 
history of PA. The ‘Minnesota Leisure Time Physical Activity’ questionnaire, used by three 
studies(37, 45, 51), has been criticised as it requires a full year’s recall which has been previously 
demonstrated to be limited by recall bias(55). We propose future researchers should use commonly 
reported and validated measures to aid synthesis of data between clinical trials. The SF-36 was used 
by 3 papers(48, 49, 52) and a 1 point increase in the Physical Component Score correlated with 
between a 1.8%(49) and 4%(52) decrease in mortality risk in renal transplant recipient and hence 
this subjective outcome measure is recommended for further use.  
 
Despite a consensus among nephrologists that PA is important for patients, assessment of physical 
function or PA advice is not a part of the routine management of CKD. Efforts to improve both 
physical function and PA by intervention should be actively encouraged in this group. In regard to 
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physical function, it appears simple objective tests, such as the TUAG and gait speed, (but perhaps 
not hand-grip strength), and self-reported measures, in particular the SF-36 (Physical Component 
Score), are useful prognostic tools in CKD. As such, research or clinical practice should use these 
physical function tests when assessing intervention effects. Complex and ‘laboratory’-based 
measures, such as those measuring VO2 or using an accelerometer or isokinetic dynamometer, 
provide high quality and reliable data, however these assessments are often impractical in a clinical 
setting and poorly tolerated by patients. More pragmatic measures of physical function and physical 
activity, such as the TUAG, gait speed, or via self-report, can be quickly and cheaply conducted in a 
clinic waiting room and hence provide a real-world method of assessing the patient’s functional 
status which correlates with morbidity and mortality. When assessing either physical functioning or 
activity, a researcher or healthcare professional should be aware of the relative strengths and 
limitations of each assessment.  
 
Conclusions 
This is the first systematic review elucidating the relationship between physical function and PA 
with clinical outcomes in the under-explored area of non-dialysis CKD. Better physical function 
and greater PA levels both correlate with improved outcomes including both reduced all-cause and 
cardio-vascular mortality risk, reduced risk of rapid decline in renal function, reduced prevalence of 
frailty and sarcopenia, and graft survival in transplant recipients. However, causality as yet remains 
unproved and further research is needed. 
 
Clinical Messages 
 Reduced physical function and PA levels are associated with increased mortality risk and 
increased risk of adverse clinical outcomes in both non-dialysis CKD and in RTR. 
 Further work is needed to investigate causality within this relationship. 
 Consistent use of outcome assessments is critical to allow meta-analysis. 
20 
 
 
 
Conflict of Interest Statement. 
The authors declare that there is no conflict of interest. 
 
Funding 
This report is independent research supported by the National Institute for Health Research 
Leicester Biomedical Research Centre and the NIHR Collaboration for Leadership in Applied 
Health Research and Care East Midlands (CLAHRC EM). We also gratefully acknowledge 
additional funding from The Stoneygate Trust.  
The views expressed are those of the author(s) and not necessarily those of the NHS, the National 
Institute for Health Research Leicester BRC, CLAHRC EM or the Department of Health and Social 
Care  
 
Contributions: Initial design: ACS, TJW, HJM: conducting searches: TJW, HJM: article retrieval: 
TJW, HJM: article review: HJM, TJW, ALC, DWG, ELW, TFO, SX, ACS: drafting manuscript: 
HJM, TJW: editing manuscript: HJM, TJW, ALC, DWG, ELW, TFO, ACS: mentoring: SJS, ACS.  
21 
 
References 
1. Byrne C CF, Castledine C, Dawnay A, Ford D, Fraser S, Lambie M, Maxwell H, Steenkamp 
R,, Wilkie M WA. UK Renal Registry, 19th Annual Report of the Renal Association. Nephron. 
2017;137 (suppl1). 
2. Padilla J, Krasnoff J, DaSilva M, Hsu CY, Frassetto L, Johansen KL, et al. Physical 
Functioning in patients with chronic kidney disease. Journal of Nephrology. 2008;21:550-9. 
3. Heiwe S, Tollback A, Clyne N. Twelve weeks of exercise training increases muscle function 
and walking capacity in elderly predialysis patients and healthy subjects. Nephron. 2001;88:48-56. 
4. Kosmadakis GC, John S, Clapp EL, Viana JL, Smith AC, Bishop NC, et al. Benefits of regular 
walking exercise in advance pre-dialysis chronic kidney disease. Nephrology Dialysis 
Transplantation. 2012;27(3):997-1004. 
5. Morie M, Reid KF, Miciek R, Lajevardi N, Choong K, Krasnoff JB, et al. Habitual Physical 
Activity Levels are Associated with Performance in Measures of Physical Function and Mobility in 
Older Men. Journal of the American Geriatrics Society. 2010;58(9):1727-33. 
6. Glenn KR, Slaughter JC, Fowke JH, Buchowski MS, Matthews CE, Signorello LB, et al. 
Physical activity, sedentary behavior and all-cause mortality among blacks and whites with diabetes. 
Annals of Epidemiology. 2015;25(9):649-55. 
7. Martinez-Gomez D, Guallar-Castillon P, Mota J, Lopez-Garcia E, Rodriguez-Artalejo F. 
Physical Activity, Sitting Time and Mortality in Older Adults with Diabetes. Int J Sports Med. 
2015;36(14):1206-11. 
8. Wu C-Y, Hu H-Y, Chou Y-C, Huang N, Chou Y-J, Li C-P. The association of physical 
activity with all-cause, cardiovascular, and cancer mortalities among older adults. Preventive 
Medicine. 2015;72:23-9. 
9. Kokkinos P. Physical activity, health benefits, and mortality risk. ISRN Cardiol. 
2012;2012:718789. 
22 
 
10. Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC. The association between mental 
health, physical function, and hemodialysis mortality. Kidney Int. 2003;63(5):1843-51. 
11. DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued 
survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis. 1997;30(2):204-12. 
12. de Oliveira MP, Kusumota L, Haas VJ, Ribeiro Rde C, Marques S, Oller GA. Health-related 
quality of life as a predictor of mortality in patients on peritoneal dialysis. Rev Lat Am Enfermagem. 
2016;24:e2687. 
13. Painter P, Roshanravan B. The association of physical activity and physical function with 
clinical outcomes in adults with chronic kidney disease. Curr Opin Nephrol Hypertens. 
2013;22(6):615-23. 
14. Kutner NG, Zhang R, Huang Y, Painter P. Gait Speed and Mortality, Hospitalization, and 
Functional Status Change Among Hemodialysis Patients: A US Renal Data System Special Study. 
Am J Kidney Dis. 2015;66(2):297-304. 
15. Johansen KL, Dalrymple LS, Glidden D, Delgado C, Kaysen GA, Grimes B, et al. Association 
of Performance-Based and Self-Reported Function-Based Definitions of Frailty with Mortality 
among Patients Receiving Hemodialysis. Clin J Am Soc Nephrol. 2016;11(4):626-32. 
16. Stack AG, Molony DA, Rives T, Tyson J, Murthy BV. Association of physical activity with 
mortality in the US dialysis population. Am J Kidney Dis. 2005;45(4):690-701. 
17. Greenwood SA, Lindup H, Taylor K, Koufaki P, Rush R, Macdougall IC, et al. Evaluation of 
a pragmatic exercise rehabilitation programme in chronic kidney disease. Nephrology Dialysis 
Transplantation. 2012;27(Supplement 3):iii126-iii34. 
18. Dontje ML, de Greef MHG, Krijnen WP, Corpeleijn E, Kok T, Bakker SJL, et al. Longitudinal 
measurement of physical activity following kidney transplantation. Clinical Transplantation. 
2014;28(4):394-402. 
23 
 
19. Aakhus S, Dahl K, Widerøe TE. Cardiovascular disease in stable renal transplant patients in 
Norway: morbidity and mortality during a 5-yr follow-up. Clinical Transplantation. 2004;18(5):596-
604. 
20. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: 
definitions and distinctions for health-related research. Public Health Rep. 1985;100(2):126-31. 
21. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting 
items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 
2015;4:1. 
22. Wells GS, B; O'Connell, D; Peterson, J; Welch, V.; Losos, M; Tugwell,P The Newcastle-
Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011 [cited 
2017 18/12/2017]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 
23. Higgins JG, S (editors). Cochrane Handbook for Systematic Reviews of Interventions. The 
Cochrane  Collaboration. 2011. 
24. Lattanzio F, Corsonello A, Montesanto A, Abbatecola AM, Lofaro D, Passarino G, et al. 
Disentangling the Impact of Chronic Kidney Disease, Anemia, and Mobility Limitation on Mortality 
in Older Patients Discharged From Hospital. J Gerontol A Biol Sci Med Sci. 2015;70(9):1120-7. 
25. Gulati M, Black HR, Arnsdorf MF, Shaw LJ, Bakris GL. Kidney Dysfunction, 
Cardiorespiratory Fitness, and the Risk of Death in Women. Journal of Womens Health. 
2012;21(9):917-24. 
26. Pechter U, Raag M, Ots-Rosenberg M. Regular aquatic exercise for chronic kidney disease 
patients: a 10-year follow-up study. Int J Rehabil Res. 2014;37(3):251-5. 
27. Wang IK, Tsai MK, Liang CC, Yen TH, Huang CC, Wen SF, et al. The role of physical 
activity in chronic kidney disease in the presence of diabetes mellitus: a prospective cohort study. Am 
J Nephrol. 2013;38(6):509-16. 
28. Beddhu S, Baird BC, Zitterkoph J, Neilson J, Greene T. Physical Activity and Mortality in 
Chronic Kidney Disease (NHANES III). Clin J Am Soc Nephrol. 2009;4(12):1901-6. 
24 
 
29. Beddhu S, Wei G, Marcus RL, Chonchol M, Greene T. Light-intensity physical activities and 
mortality in the United States general population and CKD subpopulation. Clin J Am Soc Nephrol. 
2015;10(7):1145-53. 
30. Chen JL, Lerner D, Ruthazer R, Castaneda-Sceppa C, Levey AS. Association of physical 
activity with mortality in chronic kidney disease. J Nephrol. 2008;21(2):243-52. 
31. Navaneethan SD, Kirwan JP, Arrigain S, Schold JD. Adiposity measures, lean body mass, 
physical activity and mortality: NHANES 1999-2004. BMC Nephrol. 2014;15:108. 
32. Ricardo AC, Madero M, Yang W, Anderson C, Menezes M, Fischer MJ, et al. Adherence to 
a Healthy Lifestyle and All-Cause Mortality in CKD. Clin J Am Soc Nephrol. 2013;8(4):602-9. 
33. Ricardo AC, Anderson CA, Yang W, Zhang X, Fischer MJ, Dember LM, et al. Healthy 
Lifestyle and Risk of Kidney Disease Progression, Atherosclerotic Events, and Death in CKD: 
Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 
2015;65(3):412-24. 
34. Robinson-Cohen C, Katz R, Mozaffarian D, Dalrymple LS, de Boer I, Sarnak M, et al. 
Physical Activity and Rapid Decline in Kidney Function Among Older Adults. Archives of Internal 
Medicine. 2009;169(22):2116-23. 
35. Robinson-Cohen C, Littman AJ, Duncan GE, Weiss NS, Sachs MC, Ruzinski J, et al. Physical 
Activity and Change in Estimated GFR among Persons with CKD. Journal of the American Society 
of Nephrology. 2014;25(2):399-406. 
36. Rosas SE, Reese PP, Huan Y, Doria C, Cochetti PT, Doyle A. Pretransplant Physical Activity 
Predicts All-Cause Mortality in Kidney Transplant Recipients. American Journal of Nephrology. 
2012;35(1):17-23. 
37. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. 
Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk 
factors. JAMA. 2005;293(14):1737-45. 
25 
 
38. Yango AF, Gohh RY, Monaco AP, Reinert SE, Gautam A, Dworkin LD, et al. Excess risk of 
renal allograft loss and early mortality among elderly recipients is associated with poor exercise 
capacity. Clin Nephrol. 2006;65(6):401-7. 
39. Delgado C, Grimes BA, Glidden DV, Shlipak M, Sarnak MJ, Johansen KL. Association of 
Frailty based on self-reported physical function with directly measured kidney function and mortality. 
BMC Nephrology. 2015;16. 
40. Roshanravan B, Robinson-Cohen C, Patel KV, Ayers E, Littman AJ, de Boer IH, et al. 
Association between physical performance and all-cause mortality in CKD. J Am Soc Nephrol. 
2013;24(5):822-30. 
41. Nastasi AJ, McAdams-DeMarco MA, Schrack J, Ying H, Olorundare I, Warsame F, et al. 
Pre-Kidney Transplant Lower Extremity Impairment and Post-Kidney Transplant Mortality. Am J 
Transplant. 2018;18(1):189-96. 
42. Chen IR, Wang S-M, Liang C-C, Kuo H-L, Chang C-T, Liu J-H, et al. Association of Walking 
with Survival and RRT Among Patients with CKD Stages 3-5. Clin J Am Soc Nephrol. 
2014;9(7):1183-9. 
43. Chang YT, Wu HL, Guo HR, Cheng YY, Tseng CC, Wang MC, et al. Handgrip strength is 
an independent predictor of renal outcomes in patients with chronic kidney diseases. Nephrol Dial 
Transplant. 2011;26(11):3588-95. 
44. Tsai YC, Chen HM, Hsiao SM, Chen CS, Lin MY, Chiu YW, et al. Association of physical 
activity with cardiovascular and renal outcomes and quality of life in chronic kidney disease. PLoS 
One. 2017;12(8):e0183642. 
45. Zelle DM, Corpeleijn E, Stolk RP, de Greef MH, Gans RO, van der Heide JJ, et al. Low 
physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin 
J Am Soc Nephrol. 2011;6(4):898-905. 
46. Chin HJ, Ahn SY, Ryu J, Kim S, Na KY, Kim KW, et al. Renal function and decline in 
functional capacity in older adults. Age and Ageing. 2014;43(6):833-8. 
26 
 
47. Doyle EM, Sloan JM, Goodbrand JA, McMurdo MET, Donnan PT, McGilchrist MM, et al. 
Association Between Kidney Function, Rehabilitation Outcome, and Survival in Older Patients 
Discharged From Inpatient Rehabilitation. Am J Kidney Dis. 2015;66(5):768-74. 
48. Griva K, Davenport A, Newman SP. Health-Related Quality of Life and Long-Term Survival 
and Graft Failure in Kidney Transplantation: A 12-Year Follow-Up Study. Transplantation. 
2013;95(5):740-9. 
49. Molnar-Varga M, Molnar MZ, Szeifert L, Kovacs AZ, Kelemen A, Becze A, et al. Health-
Related Quality of Life and Clinical Outcomes in Kidney Transplant Recipients. Am J Kidney Dis. 
2011;58(3):444-52. 
50. Pereira RA, Cordeiro AC, Avesani CM, Carrero JJ, Lindholm B, Amparo FC, et al. 
Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with 
mortality. Nephrol Dial Transplant. 2015;30(10):1718-25. 
51. Tikkanen-Dolenc H, Waden J, Forsblom C, Harjutsalo V, Thorn LM, Saraheimo M, et al. 
Physical Activity Reduces Risk of Premature Mortality in Patients With Type 1 Diabetes With and 
Without Kidney Disease. Diabetes Care. 2017;40(12):1727-32. 
52. Prihodova L, Nagyova I, Rosenberger J, Roland R, Groothoff JW, Majernikova M, et al. 
Health-Related Quality of Life 3 Months After Kidney Transplantation as a Predictor of Survival 
Over 10 Years: A Longitudinal Study. Transplantation. 2014;97(11):1139-45. 
53. Chen JLT, Lerner D, Ruthazer R, Castaneda-Sceppa C, Levey AS. Association of physical 
activity with mortality in chronic kidney disease. Journal of Nephrology. 2008;21(2):243-52. 
54. Chiang HH, Livneh H, Yen ML, Li TC, Tsai TY. Prevalence and correlated of depression 
among chronic kidney disease patients in Taiwan. BMC Nephrology. 2013;14(78). 
55. Richardson MT, Leon AS, Jacobs DR, Ainsworth BE, Serfass R. Comprehensive evaluation 
of the Minnesota leisure time physical activity questionnaire. Journal of Clinical Epidemiology. 
1994;47(3):271-81. 
27 
 
56. Wang IK, Tsai M-K, Liang C-C, Yen T-H, Huang C-C, Wen S-F, et al. The Role of Physical 
Activity in Chronic Kidney Disease in the Presence of Diabetes Mellitus: A Prospective Cohort 
Study. American Journal of Nephrology. 2013;38(6):509-16. 
 
  
28 
 
Table 1. Summary of findings; association between physical function with all-cause mortality or adverse clinical outcomes 
  
Study Patient characteristics 
N; CKD stage or 
RTR; mean 
age(years); % male; 
mean eGFR [SD] 
Mean 
follow-
up 
duration 
(years) 
Comparison, 
control, or 
comparator 
Outcome 
measure(s)/ 
intervention 
Main findings Mortality Hazard ratio (HR) 
[95CI] 
Chin et al 
2014(46) 
984 CKD 1-5; 76.0 
years [9.1];44%; 72.3 
[17.0] 
5  eGFR groups Self-report: 
Korean 
version of 
ADLs, 
Instrumental 
ADL 
renal function associated 
with 29.5% ADL/IADL 
scores. 
ADL/IADL scores 
associated with MR 
eGFR ≥60 HR=1.87c [1.10–
3.20] 
eGFR <59 HR= 2.53c [1.57–
4.09] 
Delgado et al 
2015(39) 
812 CKD; 52 years 
(median); 60.5%, 
mGFR=33.1 [11.7] 
17  
(median) 
Sample 
divided into 3 
categories: 
Not Frail, 
Immediate 
Frail, Frail. 
Self-report: 
MDRD 
LTPAQ; 
MDRD 
quality of 
well-being 
measure 
eGFR correlates with 
levels of self-report frailty 
and MR 
Intermediate Frail 
HR=1.47[1.14-1.90]b,c,d,f 
Frail: HR:1.71[1.26-2.30] b,c,d,f 
 
Intermediate Frail HR=1.43 
[1.11-1.83] b,c,d,e,f 
Frail HR=1.48 [1.08-2.00] b,c,d,e,f 
 
Griva et al 
2013(48) 
347 RTR; 46.55 years 
[13.96]; 54.2%; 38.54 
[14.07] 
8.57 
[6.55] 
n/a Self-report: 
HRQoL and 
SF-36  
 
Physical HRQoL and PF 
associated with MR and 
graft failure. 
All-cause mortality: 
HR=4.3 [2.72-6.78]a p<0.001. 
HR=1.82 [1.04-2.86]b,f p=0.04 
 
Graft failure:  
HR=2.99 [2.08-4.3]a p<0.001 
HR=1.57 [1.04-2.38]b,f p=0.03 
Molnar-
Varga et al 
2011(49) 
879 RTR’s; 49years 
[13]; 58%; 50 [22] 
7.83 
(median) 
n/a Self-report: 
KDQoL- 
including 
HRQoL, SF-
PCS and PF independently 
associated with mortality or 
graft loss. However, 
associations were not 
SF-36 PCS: 
HR= 0.66 [0.59-0.75]a p<0.001 
HR=0.8 [0.7-0.91]b,c,e,f p=0.001 
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36 and CES-
D scale. 
significant after adjustment 
for depression. 
 
10-point PCS yields 
18%MR; 10-point  PF 
associated with 11% MR.  
Adjusted for depression score 
HR= 0.82 [0.71-0.95]b,c,e,f 
p=0.008 
 
PF score 
HR=0.84 [0.80-0.87]a p<0.001 
HR=0.88 [0.83-0.93] b,c,e,f 
p<0.001 
Adjusted for depression score 
HR=0.89 [0.84-0.94] b,c,e,f 
p<0.001 
Prihodova et 
al 2014(52) 
151 RTR; 47.09 years 
[13.2]; 56.3%; 51.16 
[15.6] 
7.1 [2.2] N/A Self-report: 
SF-36 
survival with eGFR (2% 
per point), PCS (4% per 
point) 
Survival analysis: 
PCS HR=1.04 p<0.05a 
Doyle et al 
2015(47) 
3012 CKD 1-5; 84 
years; 41% 
12  Comparison 
across eGFR 
groups 
Self-
report/objec
tive: Barthel 
score 
discharge Barthel Score 
(i.e. PF) were associated 
with  all-cause MR 
Barthel Score ≥10,  
eGFR <30 HR=7.0  
eGFR HR=3.0 
 
Barthel Score 19-20, 
eGFR <30 HR: 1.5 
eGFR 45-90 HR=1.25 
Chang et al 
2011 
128 CKD1-5; 60.7 
years [14.8]; 46.8%; 
46.6 [28.2] 
2.825 eGFR groups Objective: 
HGS 
HGS used as measure of 
protein-energy wasting. 
 
HGS is independent 
predictor of outcome. 
Risk of all-cause mortality or 
dialysis initiation: 
HR=0.9 p=0.004 (CKD1-5) 
HR=0.91[0.83-0.99] p=0.031 
CKD3b-5  
Gulati et al 
2012(25) 
5716; 52.5years [10.8]; 
0%; 53.7 [8.3] 
15.9  n/a Objective: 
Treadmill test 
using Bruce 
protocol to 
measure 
cardiorespirat
ory fitness 
Cardiorespiratory fitness 
significantly modified the 
association between eGFR 
and mortality (p < 0.001). 
 
eGFR< 45 + fitness level < 5 
METs: MR=7.6 deaths/1000 
person-years 
 
30 
 
 
eGFR ≥ 60 + fitness level of 
> 8 METs MR=0.56 
deaths/1000 person-years 
Lattanzio et 
al 2015(24) 
487 CKD post-hospital 
discharge; 80.1 years 
[6.0]; 45.8%; 50.4 
[14.7]  
1 none Objective: 
SPPB 
MR with older age, 
hypoalbuminemia, cognitive 
impairment, impaired 
ADL’s, eGFR <30, anemia 
and SPPB < 5. 
SPPB=5-8 HR = 1.96, [0.63-
6.07]b,c 
SPPB: 0-4 HR = 5.70, [1.98-
12.4]b,c 
 
SPPB= 5-8: HR = 1.45 [0.53-
4.27]b,c,d,f 
SPPB: 0-4: HR = 2.93 [1.07-
8.63] b,c,d,f 
Nastasi et al 
2017(41) 
719 RTR; 51.6 years 
[14.2]; 62.3%;  
2 
(median) 
N/A Objective: 
SPPB 
1 point reduction in chair 
stand or walking speed score 
correlates with 1.21 and 1.5 
fold increase in mortality risk 
SPPB <10 HR=3.57 [1.83-
6.98]a p<0.001 
HR=2.3 [1.12-4.74]b,c,d,f p=0.02 
Pereira et al 
2015(50) 
287 CKD 3-5; 59.9 
years [10.5]; 62%; 25.0 
[15.8] 
Up to 
3.33  
N/A Objective: 
Sarcopenia 
measured 
using HGS 
and 
Bioelectrical 
Impedance 
Analysis  
Presence of sarcopenia 
significantly predicts all-
cause mortality. 
HR=2.89 [1.4-5.96]a p=0.004 
HR=3.58 [1.43-8.31]b,c,d 
p=0.003 
 
Roshanrava
n et al 
2013(40) 
385 CKD2-4; 61 years 
[13]; 84%; 41 [19] 
3 
(median) 
N/A Objective: 
TUAG; HGS; 
6MWD;Gait 
speed 
PF measures reliant on lower 
limb strength  30-39% 
compared to normative 
values but grip strength 
relatively preserved.  
 
MR=47 deaths per 
1000person-years. 
 
Gait speed ≤ 0.8m/s  
HR=2.45 [1.09–5.54]b,c,d,e,f (per 
0.1m/s slower HR=1.26) 
 
TUAG ≥12s  
HR=1.81 [0.92–3.56] b,c,d,e,f 
(HR=1.08 increases per 1s 
slower) 
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CKD = chronic kidney disease; RTR = renal transplant recipients; ADL = activities of daily living; eGFR = estimated glomerular filtration rate 
[ml/min/1.73m²]; HR = hazard ratio; PA = physical activity; PF = physical function; MDRD LTPAQ = Modification of Diet in Renal Disease Leisure 
Time Physical Activity Questionnaire; HRQoL= health related quality of life; SF-36 = 36-item Short Form survey; KDQoL= Kidney Disease Quality 
of Life; CES-D = Centre for Epidemiologic Centres Scale for Depression; PCS = physical composite score; SPPB = Short Physical Performance 
Battery; MR = mortality rate; MET = metabolic equivalent task; TUAG = Timed- Up-and-Go; HGS = hand grip strength; 6MWD = 6 minute walk 
distance 
 
a = unadjusted model; b = adjusted for age; c = adjusted for gender; d= adjusted for BMI; e = adjusted for eGFR; f = adjusted for additional co-variants 
(see reference for full analysis) 
  
0.1m/s gait speed 
associated with 26% risk 
of death;  
1s longer TUAG associated 
with ~8% MR  
6-min walk distance <350m 
HR=2.82 [1.17–6.92] b,c,d,e,f 
(HR=1.15 per 50m reduction) 
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Table 2. Summary of findings; association between physical activity level with all-cause mortality or adverse clinical outcomes 
 
Study Patient characteristics N; 
CKD stage or RTR; mean 
age(years); % male; mean 
eGFR [SD] 
Mean 
follow-up 
duration 
(years) 
Comparison, 
control, or 
comparator 
Outcome 
measure(s)/ 
intervention 
Main findings Mortality Hazard ratio 
(HR) [95CI] 
Beddhu et 
al 2009(28) 
15368 in full study;  
Non-CKD: 
Inactive: 48years;37%;95.6  
Insufficiently Active; 
42years;47%;94.9 
Recommended Activity: 
43years;54%;92.9 
 
CKD n=907; (eGFR<60);  
Inactive: 
73years;27%male;46.9 
Insufficiently Active: 
66years; 40%male;50.8 
Recommended Activity: 
68years;43%male;49.8 
7 for CKD 
group  
(8.8 years 
for non-
CKD 
group) 
Non-CKD 
population. 
Divided into: 
Inactive: 
Insufficiently 
Active; 
Recommende
d Activity 
Self-report: 
interviewer 
administered 
HAQ 
CKD was associated 
with a ↑prevalence of 
low PA (odds ratio 
1.30[1.03-1.64]). 
CKD:  
Insufficiently Active 
HR=0.58 [0.42-0.79]b,c,d,e,f 
Recommended Activity 
HR=0.44 [0.33-0.58] b,c,d,e,f 
 
Non-CKD group:  
Insufficiently Active HR=0.6 
[0.45-0.81] b,c,d,e,f 
Recommended Activity 
HR=0.59 [0.45-0.77] b,c,d,e,f 
Chen et al 
2008(30) 
811 CKD 3-4;52 years, 
61% ;32.5 
Not 
explicitly 
stated. 
Nil Self-report: 
interviewer 
administered 
MDRD-
LTPAQ 
No change in MR with 
PA category 
Indoor activity HR=0.94 
[0.77-1.14]b,c,e,f 
exercise HR=1.01 [0.84-
1.10] b,c,e,f 
Outdoor activity HR=0.94 
[0.80-1.10] b,c,e,f 
Chen et al 
2014(42) 
6363 CKD 3-5; 
70.1years;57%; 
10   Self-report: 
exercise 
activity with 
3month recall; 
confirmed by 
↓MR in groups that 
walked regularly. 
↑frequency of walking 
correlated with ↓MR. 
Walking 
HR=0.65;[0.51-0.81]; 
P<0.001 
RRT risk (HR=0.75; [0.69-
0.80] P<0.001 
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family/care-
giver 
 
↑duration of exercise 
HR=0.77 [0.70-0.85] 
P<0.001) 
RRT risk HR=0.89; [0.86-
0.92]; p<0.001for each 
30min increase. 
 
↑frequency of exercise  
HR=0.83[0.78-0.90] p<0.001  
RRT risk HR=0.92; [0.90-
0.94]; p<0.001 for each 
category increase. 
Navaneetha
n et al 
2014(31) 
11,586 
9,433 non-CKD; 43.9years 
[0.3]; 50.6%; 96.8 (0.4) 
 
2,153 CKD; 60.7years 
[0.7]; 43.1% [1.0]; 72.9 
[0.9] 
4.5 Non-CKD Self-report: 
Interviewer 
administered 
PA 
questionnaire 
 PA below recommended 
levels mortality HR=1.36 
[1.00-1.85]b,c,d,e,f 
 
For each log unit 
↑METS/week HR=0.97[0.95-
1.00] b,c,d,e,f 
 
PA <450 METS/week 
CKD HR= 1.34 [0.98-1.84] 
b,c,d,e,f 
Non-CKD HR=1.65 [1.19-
2.28] b,c,d,e,f 
 
PA <450 METS/week 
CKD HR= 1.36 [1-1.85] 
b,c,d,e,f 
Non-CKD =1.65 [1.21-2.26] 
b,c,d,e,f 
Ricardo et 
al 2013(32) 
2288 CKD 1-4; 59 years; 
40%; 78 
13  Self-report - 
interviewer 
Individuals in the 
highest eGFR strata 
Insufficient PA 
HR=0.76 [0.6-0.96]b,c 
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administered 
HAQ 
were less likely to 
adhere to the 
recommended level of 
PA than those in the 
lowest eGFR strata 
(42% v 34%) 
HR = 0.86 [0.67–1.10]b,c,e,f p 
= 0.22 
 
Recommended PA  
HR=0.73 [0.57-0.92]b,c 
HR = 0.80 [0.65–0.99] b,c,e,f p 
= 0.04 
Ricardo et 
al 2015(33) 
3006 CKD eGFR20-
70;58years [11]; 52%; 
43[14] 
4 (median) N/A Self-report: 
MESA.  
 Less than ideal PA HR=0.74 
[0.57-0.96]b,c,f 
Ideal PA HR 0.60 [0.49-0.74] 
b,c,f 
Robinson-
Cohen et al 
2014(35) 
256 CKD3-4; 82%; 
 
0 min/wk - 61.8[11.3] 
years; 37.8[20.1] 
1-60 min/wk- 58.8[12.8] 
years: 41.0[18.6] 
60-150 min/wk- 61.7[12] 
years; 37.4[18.2] 
>150 min/wk- 61.7[12.5] 
years; 40.5[14.0] 
3.7 
(median) 
Subdivided 
into groups 
based on 
min/week 
PA; 
Self-report: 
Four-Week 
Physical 
Activity 
History 
Questionnaire 
↓annual decline in 
eGFR (2.8%) in highest 
PA categories  
 
Each ↑60-min PA 
associated with 
~0.5%/yr slower 
decline.  
HR for incident ESRD 
Any PA HR=0.59b,c [0.28-
1.24] p=0.19 
Per 60min/week increment 
HR=0.9b,c [0.74-1.10] p=0.32 
Rosas et al 
2012(36) 
507 RTR;47.8 years[12.8]; 
61%  
 
8.4  Self-report: 
Physical 
Activity scales 
for the Elderly 
Inactive: MR 36.3% 
Moderate: MR 23.3%  
Active: MR: 16.3% 
METS (per 10 unit change) 
HR=0.91a [0.87-0.96] 
p<0.001 
HR=0.93b,c [0.88-0.97] 
p=0.002 
 
Moderate tertile  
HR=0.81a [0.55-1.2]; p=0.3 
HR=0.91b,c,f [0.61-1.36]; 
p=0.7 
 
Active tertile  
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HR=0.45a [0.29-0.72]; 
p=0.001 
HR=0.53b,c,f [0.33-0.84]; 
p=0.01 
 
Shlipak et 
al 2005(37) 
6495  
CKD group (eGFR<60) 
1249;75[6]years;47%;50[1.
73] 
Non CKD group 
4559;772[5]years;41%;87[
20] 
8.6 Non-CKD Self-report: 
MLTPAQ 
CV MR = 32 deaths per 
1000person-years in 
CKD; 16 deaths per 
1000person-years in 
non-CKD. 
CKD: Low PA  
HR=1.58b,c,f [1.25-2.01]; 
p<.001;  
 
non-CKD: low PA 
HR=1.31b,c,f [1.10-1.57] 
p.003;  
Tikkanen-
Dolenc et al 
2017 
310 CKD, including RTR 
(n=64) and dialysis-
dependent patient (n=36) 
(2639 in full study) 
11.4  Self-report: 
Finnish 
version of 
MLTPAQ  
 HR for CKD & RTR 
(excluding dialysis-
dependent) 
LTPA (moderate/high LTPA 
used as reference) 
Low HR=1.99 [0.95-4.15] a 
Low HR=2.12 [0.99-4.57] c,f 
 
Exercise Intensity 
(moderate/high intensity used 
as reference) 
Low HR=3.11 [1.31-7.38] a 
Low HR=2.4 [0.99-5.81]c,f 
 
Exercise Frequency 
(moderate/high freq used as 
reference) 
Low HR=2.85 [1.4-5.8] a 
Low HR=2.6 [1.15-5.84] c,f 
 
Exercise duration (high 
duration used as reference) 
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Low HR=4.03 [1.8-9.01] a 
Low HR=2.87 [1.21-6.84] c,f 
Wang et al 
2013(27) 
445,075;  
41.1years[13.8];50% 
 
42,757 CKD, no DM; 
49.4years[16.5];52.3%;69.4 
 
7863 CKD + DM; 
59.3years[11.8];54.9%;66.2 
Up to 12  Healthy 
population; 
CKD;  
CKD + DM 
Self-report: 
questionnaire 
(not specified)  
MR per 100,000 
person-years: 
Healthy population: 
inactive: 362 [352-372] 
Low-active: 314 [300–
328] 
Fully active: 281.4 
[269–295] 
CKD+DM  
Inactive: 1,317.2 
[1,191–1,456] 
Low-active: 912.2 
[744-1118] 
Fully active:871 [745–
1018] 
DM/CKD: 
low-active HR= 0.78b,c [0.65 
– 0.92]  
fully active HR=0.63b,c [0.55 
– 0.73]  
 
Yango et al 
2006(38) 
402 RTR however data 
only presented for n=64 
>60years 
64years[4];65%  
 
3  Retrospective 
Cohort study 
Self-report: 
PA level 
assessed based 
on history 
obtained by the 
examining 
physician. 
 
1 year survival rate: 
Overall 78% 
Active 94% 
Inactive 24% 
 
3 year survival rate: 
Overall 71% 
Active 24% 
Inactive 24% 
None calculated 
Zelle et al 
2011(45)  
540 RTR patients: 51years 
[12]; 54%  
5.3 [4.7-
5.7]  
N/A Self-report: 
Interviewer-led 
Tecumseh 
Occupational 
Activity 
Questionnaire; 
MLTPAQ 
 HR=0.58 [0.4- 0.70]a 
p<0.001 
HR=0.67 [0.54-0.83]b,c 
p<0.001 
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Robinson-
Cohen et al 
2009(34) 
4011 
PA score 2-3: 
896;72.8years [5.4]; 30.7%; 
75.1[18.3] 
 
PA score 4-6: 2137; 72.0 
years [5.1]; 
40.3%;78.9[17.2]  
 
PA score 7-8: 896;71.2 
years [4.4];56.7%; 
81.1[16.2] 
7 (median) Divided into 
categories 
based on PA 
score 
 
Objective and 
self-report: 
Gait speed 
used in 
combination 
with PA 
questionnaires 
to give 
cumulative PA 
score. 
 
Lower risk of RDKF 
was found with 
increased PA scoreb,c,d,f  
 
Same relationship could 
be seen when the results 
were stratified into 
groups using eGFR 
HR of developing RDKFb,c,d,f 
 
eGFR<60  
PA score 4-6 HR=0.75 [1.45-
1.27]  
PA score 7-8 HR=0.78 [1.4-
1.51] 
p=0.44 
 
eGFR 60-89  
PA score 4-6 HR=0.88 [0.71-
1.09] 
PA score 7-8 HR=0.63 [0.47-
0.85] 
p=0.02 
 
eGFR90-119 
PA score 4-6 HR=0.72 [0.56-
0.92] 
PA score 7-8 HR=0.69 [0.51-
0.94] 
P=0.04 
Beddhu et 
al 2015(29) 
3626 in full study; 383 
CKD 
2.86 
[0.64]  
 
Non-CKD 
population 
Objective: 
Accelerometry 
↑sedentary duration was 
associated with 
↑mortality  
Non CKD: HR 1.18 [1.09-
1.28]b,c,f 
CKD subgroup: HR 1.16 
[1.04-1.13] b,c,f 
Pechter et 
al 2014(26) 
26 CKD;  
Intervention: 7; 52years; 
42%;50.9[9.2] 
Control group; 9; 48 years; 
50%; 51.6[7.1] 
10 Sedentary 
control group 
who did not 
consent to 
exercise 
Intervention: 
regular aquatic 
exercise for 10 
years (>32 
weeks a year, 
30 mins, 2x a 
week) 
Active group:  
0% MR; 0% 
commenced dialysis  
Control group: 55% 
MR; 22% commenced 
dialysis  
Not reported. 
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Tsai et al 
2017(44) 
161 CKD1-5; 67.2 years 
[7.8]; 54%; 34.5[28.8] 
2.425 CKD1-3 v 
CKD4-5 
comparison 
Objective: 
HGS 
30s chair stand 
2min step 
 
Subjective: 
Taiwan 
version of the 
WHO QoL-
BREF 
Interviewer 
administered 
HAQ 
COMBINED PA & 
PF 
 
No relationship 
between PA and 
outcomes 
Risk of initiation of dialysis: 
High HGS HR=0.89[0.84-
0.96] 
High 2min step 
HR=0.304[0.01-0.95] 
 
eGFR = estimated glomerular filtration rate; RTR = renal transplant recipient; HR = hazard ratio; PA = physical activity; PF = physical function; HAQ 
= Household Adult Questionnaire; MDRD LTPAQ = Modification of Diet in Renal Disease Leisure Time Physical Activity Questionnaire; MESA= 
Multi-Ethnic Study of Atherosclerosis Typical Week Physical Activity Survey; MLTPAQ = Minnesota Leisure Time Physical Activity Questionnaire; 
MR = mortality rate; RRT risk = risk of requiring renal replacement therapy; CV = cardiovascular; RDKF = rapid decline in kidney function; 
 
a = unadjusted model; b = adjusted for age; c = adjusted for gender; d = adjusted for BMI; e = adjusted for eGFR; f = adjusted for plus additional co-
variants (see reference for full analysis) 
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Table 3. Papers reviewed, Newcastle-Ottawa Scale score, and bias criteria 
 Study Selection /4 Comparability /2 Outcome /3 AHRQ 
criteria  
1 Beddhu et al 2009(28)    Good 
2 Beddhu et al 2015(29)    Good 
3 Chang et al 2011(43)    Good 
4 Chen et al 2008(30)    Fair 
5 Chen et al 2014(42)    Fair 
6 Chin et al 2014(46)    Poor 
7 Delgado et al 2015(39)    Fair 
8 Doyle et al 2015(47)    Good 
9 Griva et al 2013(48)    Good 
10 Gulati et al 2012(25)    Good  
11 Lattanzio et al 2015(24)    Good 
12 Molnar-Varga et al 
2011(49) 
   Fair 
13 Nastasi et al 2017    Good 
14 Navaneethan et al 
2014(31) 
   Good 
15 Pechter et al 2014(26)  -  Poor 
16 Pereira et al 2015(50)    Good 
17 Prihodova et al 
2014(52) 
   Good 
18 Ricardo et al 2013(32)    Fair 
19 Ricardo et al 2015(33)    Fair 
20 Robinson-Cohen et al 
2009(34) 
   Good 
21 Robinson-Cohen et al 
2014(35) 
     Good 
22 Rosas et al 2012(36)    Good 
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23 Roshanravan et al 
2013(40) 
   Good  
24 Shlipak et al 2005(37)    Good 
25 Tikkanen-Dolenc et al 
2017 
   Good 
26 Tsai et al 2017(44)    Good 
27 Wang et al 2013(56)    Fair  
28 Yango et al 2006(38)    Good  
29 Zelle et al 2011(45)    Good 
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Figure 1. PRISMA flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PubMed = National Centre for Biotechnology Information (NCBI) PubMed (which includes 
the Medical Literature Analysis and Retrieval System Online (MEDLINE)); CENTRAL = 
Cochrane Central Register of Controlled Trials; WoS = Web of Science (which includes the 
PubMed = 2,685 records identified = 22 saved based on screening of title/abstract 
CENTRAL = 557 records identified = 5 saved based on screening of title/abstract 
Web of Science = 2,611 records identified = 214 saved based on screening of title/abstract 
EMBASE = 446 records identified = 8 saved based on screening of title/abstract 
Duplicates removed = 211 
 
Additional sources identified during review of full-text records = 1 
 
Trials included in review and data extracted = 25 
 
Removed as did not meet criteria = 14 
Records after duplicated removed = 38 
Full-texts of records screened for full inclusion and exclusion criteria = 24 
 
Reviewed search in December 2017 – 4 additional papers identified. 
Total included in review and data extracted = 29 
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KCI-Korean Journal Database, MEDLINE, Russian Science Citation Index, and SciELO 
Citation Index); EMBASE = Excerpta Medica database 
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Supplementary material 1.  
 
Example search strategy from NCBI PubMed 
 
User query using pre-defined search terms 
“kidney diseases” AND “physical activity” AND “mortality” AND (Clinical Trial[ptyp] 
AND Humans[Mesh]) 
 
Query Translation 
("kidney diseases"[MeSH Terms] OR ("kidney"[All Fields] AND "diseases"[All Fields]) OR 
"kidney diseases"[All Fields]) AND ("exercise"[MeSH Terms] OR "exercise"[All Fields] OR 
("physical"[All Fields] AND "activity"[All Fields]) OR "physical activity"[All Fields]) AND 
("mortality"[Subheading] OR "mortality"[All Fields] OR "mortality"[MeSH Terms]) AND 
(Clinical Trial[ptyp] AND "humans"[MeSH Terms]) 
 
Individual translations  
kidney diseases 
"kidney diseases"[MeSH Terms] OR ("kidney"[All Fields] AND 
"diseases"[All Fields]) OR "kidney diseases"[All Fields] 
physical 
activity 
"exercise"[MeSH Terms] OR "exercise"[All Fields] OR ("physical"[All 
Fields] AND "activity"[All Fields]) OR "physical activity"[All Fields] 
mortality 
"mortality"[Subheading] OR "mortality"[All Fields] OR "mortality"[MeSH 
Terms] 
Humans[Mesh] "humans"[MeSH Terms] 
 
PRISMA 2009 Checklist 
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Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4,5 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
6,7 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
See 
Supp. 
material 
1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
7 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
8 
PRISMA 2009 Checklist 
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
8 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
8 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  8 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
N/A 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
8 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
9 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
9 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table 3 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table 1 
and 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Table 3 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
PRISMA 2009 Checklist 
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Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
15-19 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  19 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
19,20 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org. Page 2 of 2  
 
